#China #Shanghai #Aphranel CaHA Filler #Moyom Biotechnology #China Medical Approval

A New Era in Medical Aesthetics: Aphranel® MagiCCrystal CaHA Filler

In a significant development for the medical aesthetics industry, Shanghai Moyom Biotechnology's flagship product, Aphranel® MagiCCrystal CaHA Filler, has recently received a Class III Medical Device Certificate from the China National Medical Products Administration (NMPA). This certification marks it as the first injectable calcium hydroxylapatite microsphere (CaHA) product approved in China for enhancing facial soft tissues.

This milestone doesn’t just raise regulatory standards in China’s aesthetic market; it signifies a commitment to safety and efficacy in bio-stimulating solutions, setting a new benchmark for quality in the global market.

Technological Innovations at the Core

The rise of CaHA microspheres has been propelled by their remarkable biocompatibility and biodegradability, with their market adoption exceeding that of poly-L-lactic acid (PLLA) by 71%. Moyom has leveraged its proprietary technology to manufacture the Aphranel® MagiCCrystal CaHA Filler with meticulously regulated microsphere size (30-35μm) and a unique through-hole structure. This innovation increases the porosity by 40% compared to existing solutions, with a unit volume output boasting more than six times the microsphere density of competing products. The advanced viscoelastic modulus of 5500Pa facilitates a long-lasting, three-dimensional support structure essential for effective facial rejuvenation.

Utilizing a pre-mixing technology of CaHA and carboxymethyl cellulose (CMC), the resulting product ensures smoother injection dynamics and uniform dispersion of particles. Rigorous testing has evidenced that the inflammation rate is 30% lower than leading alternatives, and the product is fully biodegradable, further enhancing its appeal.

Expanding Frontiers in Medical Aesthetics

To bolster this development, Moyom Biotechnology has established a robust innovation network characterized by an integrated approach—combining research and development in China with local adaptation strategies. Collaborations with prestigious institutions, such as Nanjing Tech University and the Chinese Academy of Sciences, are paving the way for advancements in biomaterial technology.

Furthermore, clinical validation is reinforced through partnerships with esteemed establishments like the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences and the Shanghai Ninth People's Hospital, thereby ensuring that clinical trials are both thorough and reliable. Their international outreach includes the establishment of joint laboratories with aesthetics experts across Germany and Brazil, facilitating localized technological adaptations.

The core team at Moyom boasts PhD holders from top universities such as Fudan University and Shanghai Jiao Tong University, along with specialists from renowned healthcare enterprises. This diverse expertise fuels innovation, merging technical proficiency with creative design principles.

Financial Growth and Industry Impact

In 2024, the company secured close to 100 million RMB in Series B+ funding, guided by Boyuan Capital and SAIC Hengxu Capital, with overall financing surpassing 500 million RMB. These funds will empower further globalization efforts and the development of next-generation absorbable implants.

The approval of Aphranel® MagiCCrystal CaHA Filler is viewed as a critical juncture within the industry's compliance landscape. As stated by the CEO of Moyom Biotechnology, "We are dedicated to providing safer, more accessible solutions to the global medical aesthetics community through our technological innovations, driving the sustainable evolution of the sector." This commitment underlines the company's proactive stance in shaping the future of medical aesthetics, ensuring products meet the highest available standards.

As the aesthetics market continues to evolve, innovations like the Aphranel® MagiCCrystal CaHA Filler demonstrate the potential to transform safety and efficacy within the industry, ultimately benefiting professionals and patients alike.